Shin Nippon Biomedical Laboratories, Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Analyst Recommendations 2 analysts
Updated 2026/06/01Earnings Calendar
Updated 2026/06/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2025/02/04 | ¥21.80 | ¥45.02 | +106.5% |
| 2024/08/05 | ¥24.97 | ¥2.93 | -88.3% |
| 2024/02/01 | ¥41.02 | ¥19.90 | -51.5% |
| 2023/11/07 | ¥26.97 | ¥38.26 | +41.9% |
Shareholder Composition
Updated 2026/06/01Major Holders
Updated 2026/06/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
280.6K | +6.85% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
187.9K | +11.31% | |
|
WisdomTree Trust-WisdomTree Japan Hedged Equity Fund
|
141.0K | +0.43% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard FTSE All-World ex-US Small-Cap
|
71.0K | -5.33% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Small-Cap Equity ETF
|
46.3K | -1.15% | |
|
VANGUARD Intl Eqy. INDEX Fd.S-Vanguard Pacific Stock Index Fd.
|
25.1K | +8.19% |
Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥30 | -40.0% |
| 2025 | ¥50 | 0.0% |
| 2024 | ¥50 | 0.0% |
| 2023 | ¥50 | -16.7% |
| 2022 | ¥60 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥25,091M | ¥26,450M | ¥32,414M | ¥32,525M |
| Gross Profit | ¥13,047M | ¥14,283M | ¥16,961M | ¥16,239M |
| Operating Income | ¥5,245M | ¥4,162M | ¥2,985M | ¥2,654M |
| Pretax Income | ¥7,885M | ¥7,113M | ¥6,216M | ¥6,541M |
| Net Income | ¥6,060M | ¥5,531M | ¥4,925M | ¥4,567M |
| EPS | ¥145.56 | ¥132.86 | ¥118.29 | ¥109.69 |
| Operating Margin | 20.90% | 15.74% | 9.21% | 8.16% |
| Balance Sheet | ||||
| Total Assets | ¥57,242M | ¥76,302M | ¥92,417M | ¥105,056M |
| Total Equity | ¥26,212M | ¥34,114M | ¥40,023M | ¥43,121M |
| Total Liabilities | ¥31,030M | ¥42,188M | ¥52,394M | ¥61,935M |
| Cash | ¥10,533M | ¥10,275M | ¥12,032M | ¥18,536M |
| Interest-bearing Debt | ¥18,761M | ¥26,187M | ¥34,474M | ¥41,259M |
| Equity Ratio | 45.79% | 44.71% | 43.31% | 41.05% |
| D/E Ratio | 0.72 | 0.77 | 0.86 | 0.96 |
| Cash Flow | ||||
| Operating CF | ¥4,004M | ¥2,107M | ¥7,035M | ¥8,327M |
| Investing CF | -¥5,931M | -¥6,908M | -¥11,691M | -¥6,791M |
| Financing CF | ¥6,266M | ¥5,319M | ¥5,914M | ¥4,514M |
| Free CF | -¥952M | -¥6,499M | -¥3,897M | ¥2,991M |
| Efficiency | ||||
| ROE | 23.12% | 16.21% | 12.31% | 10.59% |
| ROA | 10.59% | 7.25% | 5.33% | 4.35% |
Latest IR Information
-
Q1 Fiscal Year ending March 2027 Financial Results Briefing Materials
Overview of the Q1 FY ending March 2027 results. Revenue increased versus the prior period, with improvements in operating income and ordinary income. The briefing material includes segment trends, outlook, and a Q&A section. Key topics highlighted include new order...
Read more -
Notice Regarding Revisions to Consolidated Earnings Forecast for the Second Quarter of the Fiscal Year Ending March 2027
Revised the consolidated earnings forecast for the second quarter of the fiscal year ending March 2027. Net sales revised up from 16,596 million yen to 17,154 million yen (+558 million yen, +3.4%), operating income revised up from 463 million yen...
Read more -
Fiscal year ending March 2027 Q1 Financial Summary (Japan GAAP) (Consolidated)
Sales of 7,868 million yen for Q1, a quarterly high; operating income of 521 million yen, returning to profit. For the full-year 2027, revisions to the previously announced earnings guidance have been disclosed. Overseas orders surged, and the NR profit...
Read more -
Nippon Steel to Announce FY2026 Dividend｜Planned Annual Dividend of 50 Yen
Nippon Steel has decided to pay a final dividend of 30 yen per share for FY2026, resulting in an annual dividend of 50 yen. The same dividend amount is planned to continue for FY2027, prioritizing stable dividends funded by retained...
Read more -
Notice Regarding Revision of Full-Year Consolidated Earnings Forecast for the Fiscal Year Ending March 2026
The full-year sales forecast for the fiscal year ending March 2026 has been revised to 306.98 billion yen (7.7% decrease from previous forecast), operating income to 2.6 billion yen (26.8% decrease), and ordinary income to 5.353 billion yen (9.7% decrease).
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥2,340
Rating Score: 2.00 (Based on 2 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels. In addition, it operates hotels accommodations facilities under the Villa Amafuru Oka and HOTEL Freesia names; and develops and operates geothermal and hot spring thermal power plants. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.
